Nuvaxovid includes an engineered fragment of the spike protein itself—albeit one without the genetic material that causes actual disease. It’s not a totally new approach to vaccine design.

Nuvaxovid is supplied in a single-dose prefilled syringe containing 0.5mL suspension for intramuscular injection; it should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F).

About Nuvaxovid™ (NVX-CoV2373) NVX-CoV2373 is a protein-based vaccine made by creating copies of the surface spike protein of SARS-CoV-2 that causes COVID.

--Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Health Canada has approved a ...

Alas, Nuvaxovid didn't live up to its promise in the second quarter. During the period, Novavax reported total revenue of $185.9 million, for a substantial 37.6% year-over-year decline.

Nuvaxovid is also available for use as a booster in adults aged 18 and older in the U.S., European Union, Japan, Australia, New Zealand, Switzerland, and Israel. In addition, ...

Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax (NVAX) in the EU Marketing Authorization includes use of Nuvaxovid™ as a primary series in ...

Nuvaxovid is fully approved for marketing throughout the European Union but it's only available under an Emergency Use Authorization in America. Product sales rose to $90 million in Europe during ...

While the company recorded $88.3M in revenue for Q4 with a ~70% YoY slump exceeding the consensus by ~3.9M, its product sales, driven by its Nuvaxovid COVID shot, plunged ~80% YoY to $50.1M.

Novavax, Inc., a Gaithersburg-based, global company advancing protein-based vaccines with its novel Matrix-M adjuvant, has been granted full marketing ...

GAITHERSBURG, Md., Dec. 7, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious ...